Humacyte (HUMA) Total Debt (2020 - 2026)

Humacyte (HUMA) has reported Total Debt for 7 consecutive years, with $36.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Debt fell 47.0% year-over-year to $36.3 million in Q2 2026; TTM through Jun 2026 was $36.3 million, a 47.0% decrease from a year earlier, with the FY2025 full-year figure at $35.4 million, up 3904.97% from the prior year.
• Total Debt was $36.3 million for Q2 2026 at Humacyte, up from $35.9 million in the prior quarter.
• Over five years, Total Debt peaked at $68.5 million in Q2 2025 and troughed at $885000.0 in Q4 2024.
• A 5-year average of $39.1 million and a median of $36.1 million in 2023 frame the typical range for Total Debt.
• Across the five-year window, Total Debt soared 299900.0% in 2022 and tumbled 97.71% in 2024, its largest moves.
• Over 5 years, Total Debt stood at $28.9 million in 2022, then surged by 33.53% to $38.6 million in 2023, then plunged by 97.71% to $885000.0 in 2024, then jumped by 3904.97% to $35.4 million in 2025, then rose by 2.48% to $36.3 million in 2026.
• The last three Total Debt figures came in at $36.3 million (Q2 2026), $35.9 million (Q1 2026), and $35.4 million (Q4 2025), per Business Quant data.